<DOC>
	<DOCNO>NCT02505334</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare efficacy safety liraglutide 1.8 mg/day liraglutide 0.9 mg/day Japanese subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Safety Liraglutide 1.8 mg/Day Liraglutide 0.9 mg/Day Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female Japanese subject least 20 year age time inform consent Type 2 diabetes subject ( diagnose clinically ) least 6 month prior screen HbA1c 7.510.0 % [ 58 mmol/mol86 mmol/mol ] ( inclusive ) Subjects stable therapy one OAD ( oral antidiabetic drug ) ( stable therapy define unchanged medication unchanged dose ) least 60 day screen accord approve Japanese label Treatment insulin within 12 week prior screen Treatment medication indication diabetes obesity state inclusion criterion period 60 day screen Screening calcitonin equal 50 ng/l History pancreatitis ( acute chronic ) Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia type 2 ( MEN 2 ) Subjects presently classified New York Heart Association ( NYHA ) Class IV Within past 180 day follow : myocardial infarction , stroke hospitalisation unstable angina and/or transient ischemic attack Diagnosis malignant neoplasm within last 5 year ( except basal squamous cell skin cancer , polyp insitu carcinoma ) Any condition , opinion investigator might jeopardise subject 's safety compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>